Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBC1 domain family member 9 antisense RNA 1 (TBC1D9-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the TBC1D9 gene. Like other antisense RNAs, TBC1D9-AS1 is thought to regulate expression of its sense counterpart (TBC1D9) or other genes through mechanisms such as transcriptional interference, chromatin modification, or mRNA stability. Antisense RNAs such as TBC1D9-AS1 are generally important for fine-tuning gene expression and have been shown to play roles in both normal physiology and disease by affecting gene regulation at multiple stages, but no literature directly implicates TBC1D9-AS1 in human disease or establishes it as a direct therapeutic target at this time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBC1 domain family member 9 antisense RNA 1 (TBC1D9-AS1).